Orion Market Research (OMR) recently published a market research report on Global Eye Care Surgical
Market. According to OMR analysis, the global Eye care Surgical Market is expected to grow significantly
during the forecast period 2018-2023 due to increasing prevalence of ophthalmic diseases. Additionally, the
global eye-care surgical market is segmented on the basis of type, end-user and regional outlook. The report
provides detailed & insightful chapters which include market overview, key findings, strategic
recommendations, market estimations, market determinants, key company analysis, market insights,
company profiling, market segmentation, geographical analysis, analyst insights and predictive analysis of the
market.
Full report of global Eye care Surgical Market is available at https://www.omrglobal.com/industry-
reports/eye-care-surgical-market/
Increasing prevalence of ophthalmic diseases is primarily supporting the growth of the global Eye care
Surgical Market. According to Prevent Blindness, in the US, over 25 million Americans have cataract
disease. This number is expected to reach 38.5 million by 2035 and 45.6 million by 2050. Moreover,
according to National Center for Biotechnology Information (NCBI), cataract surgery is one of the most
common surgical procedures performed in Germany where approximately 800,000 people have this
surgery every year. This number represents that cataract is one of the major ophthalmic diseases that
requires proper eye care treatment. Hence, cataract surgery is performed to treat cataracts. The
condition causes blurry vision which creates difficulty to perform normal day-to-day activities. Hence,
ophthalmologists suggested cataract surgery for the treatment of the condition by removing the eye
lens and in certain cases, replace it with an artificial lens. As a result, it is encouraging the growth of the
global Eye care Surgical Market.
Moreover, innovations in minimally invasive surgeries has witnessed for more effective treatment of
ophthalmic conditions. For instance, in April 2017, Alcon Laboratories, Inc. declared the EU launch of
CyPass Micro-Stent. It is a micro-invasive glaucoma surgical device (MIGS) aimed to treat patients
suffering from mild to moderate primary open-angle glaucoma (POAG). Additionally, it can also be used
as a standalone procedure among patients with POAG who are unsuccessful with earlier medical
treatment. This new offering by Alcon Laboratories, Inc. enables to meet the needs of significant
number of glaucoma patients. The device is intended to reduce intraocular pressure among people with
POAG. Such innovations in minimally invasive surgical devices is expected to accelerate the demand for
minimally invasive surgeries for the treatment of ophthalmic diseases and will enable the market to
grow further.